[Resistant cytomegalovirus infection in related donor kidney allograft recipients].
OBJECTIVE
To clarify whether cytomegalovirus (CMV) infection can affect the results of living related donor kidney transplantation.


METHODS
A study group included 17 (7.27%) patients (10 men and 7 women; 8 children and 9 adults) aged 3 to 51 years who had developed resistant CMV infection. For comparative analysis, a control group was formed from 113 patients (61 men and 52 women; 40 children and 73 adults) aged 1 to 61 years, whose CMV polymerase chain reaction (PCR) had always been negative, i.e. CMV DNA was absent. The duration of CMV infection episodes was 44 to 232 days.


RESULTS
The patients were given valganciclovir in a dose of 450 mg/day. CMV PCR was negative in all the patients at the end of therapy. None of the patients died; one graft was lost. In the control (negative CMV PCR) group, 6 grafts were lost in 113 patients lost and 4 patients died. Statistical analysis showed that the results of related donor kidney transplantation were virtually equal.


CONCLUSIONS
Suppression of resistant CMV infection can be achieved with the longer use of valganciclovir or its higher dose. CMV infection fails to affect the results of related donor kidney transplantation.
Acad. B.V. Petrovsky Russian Surgery Research Center, Moscow, Russia.
V A
VA
Goryainov
Acad. B.V. Petrovsky Russian Surgery Research Center, Moscow, Russia.
M M
MM
Kaabak
Acad. B.V. Petrovsky Russian Surgery Research Center, Moscow, Russia.
N N
NN
Babenko
Acad. B.V. Petrovsky Russian Surgery Research Center, Moscow, Russia.
E N
EN
Platova
Acad. B.V. Petrovsky Russian Surgery Research Center, Moscow, Russia.
A G
AG
Aganesov
Acad. B.V. Petrovsky Russian Surgery Research Center, Moscow, Russia.
M M
MM
Morozova
Acad. B.V. Petrovsky Russian Surgery Research Center, Moscow, Russia.
V V
VV
Panin
D000293:Adolescent; D000998:Antiviral Agents / Q000008:administration & dosage; D002675:Child, Preschool; D003587:Cytomegalovirus / Q000187:drug effects* / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000209:etiology / Q000401:mortality; D004279:DNA, Viral / Q000032:analysis; D060467:Disease Resistance / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000379:methods; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy / Q000401:mortality / Q000821:virology; D012426:Russia / Q000453:epidemiology; D013997:Time Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D000077562:Valganciclovir
D000998:Antiviral Agents; D004279:DNA, Viral; D007166:Immunosuppressive Agents; D000077562:Valganciclovir; D015774:Ganciclovir